3-deazauridine and Leukemia--Myeloid--Acute

3-deazauridine has been researched along with Leukemia--Myeloid--Acute* in 6 studies

Reviews

1 review(s) available for 3-deazauridine and Leukemia--Myeloid--Acute

ArticleYear
Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications.
    Blood, 1983, Volume: 62, Issue:4

    A prominent phenotypic abnormality of human acute myelogenous leukemia cells is the inability of the cells to differentiate to functional mature cells; instead, the cells are blocked at an early stage of development and remain in the proliferative pool and rapidly accumulate. Investigation of the induction of myeloid leukemic cell differentiation has made recent advances with the development of several human myelogenous leukemia cell lines. The lines provide models to study the biology of myeloid differentiation and to identify inducers of differentiation of myeloid leukemic blood cells. This review critically examines the inducers of leukemic cell differentiation and their potential therapeutic importance.

    Topics: 3-Deazauridine; Acetamides; Alkaloids; Animals; Calcitriol; Cell Differentiation; Cell Line; Cells, Cultured; Dimethyl Sulfoxide; Glycoproteins; Granulocytes; Growth Inhibitors; Humans; Hypoxanthines; Interferons; Interleukin-6; Leukemia Inhibitory Factor; Leukemia, Myeloid, Acute; Lymphokines; Lyngbya Toxins; Macrophages; Mice; Phorbol Esters; Piperidones; Polyethylene Glycols; Tretinoin

1983

Other Studies

5 other study(ies) available for 3-deazauridine and Leukemia--Myeloid--Acute

ArticleYear
Effects of pyrimidine antagonists on sialic acid regeneration in HL-60 cells.
    Cancer research, 1985, Volume: 45, Issue:7

    Because alterations in cell membrane sialoglycoconjugates can affect the behavior of neoplastic cells, we investigated the effects of in vitro treatment with antimetabolites used in cancer therapy on the expression of membrane sialic acid in cultured HL-60 leukemic cells. In these studies, cells were incubated with Vibrio cholerae neuraminidase to remove surface sialic acid. Reappearance of membrane sialic acid during drug treatment was followed (a) by measuring changes in radioactive surface labeling of viable cells with sodium metaperiodate-sodium[3H]-borohydride, (b) by measuring the decline in accessible surface galactosyl receptor sites which occurred coincident with membrane sialic acid replacement, and (c) by measuring the incorporation of [3H]glucosamine into membrane-associated neuraminidase-labile sialic acid. We were especially interested in learning whether drugs that affect intracellular pools of cytidine triphosphate (CTP), an important nucleotide intermediate in sialylation reactions, could inhibit regeneration of membrane sialic acid. 3-Deazauridine, a competitive inhibitor of CTP synthetase, depleted CTP pools and curtailed surface membrane resialylation with little or no effect on synthesis of de novo sialic acid from precursor sugars. The addition of cytidine restored CTP pools and sialic acid regeneration. Acivicin, a glutamine antagonist, also depleted CTP pools and curtailed surface membrane resialylation. In addition, it retarded de novo synthesis of sialic acid. The addition of cytidine restored intracellular CTP pools and sialic acid regeneration. However, both cytidine and guanosine were required to restore sialic acid synthesis from precursor sugars. 1-beta-D-Arabinofuranosylcytosine, a competitive inhibitor of sialic acid synthetase and of sialyltransferase, inhibited both de novo sialic acid synthesis and membrane resialylation. Only the latter effect was reversed by the addition of exogenous cytidine. Hydroxyurea, an agent shown previously to inhibit glycoconjugate production in hamster fibroblasts, curtailed membrane resialylation and de novo synthesis of sialic acid without depleting CTP pools. Doxorubicin, at levels that caused marked arrest of cell proliferation, had no effect on sialic acid synthesis or expression on the membrane surface. These data suggest that antimetabolites, apart from their cytotoxic effects or effects on cellular growth, may directly inhibit the expression of membrane sialic acid.(ABSTRACT TRUNCATE

    Topics: 3-Deazauridine; Agglutination; Antimetabolites, Antineoplastic; Cell Line; Cytarabine; Cytidine Triphosphate; Doxorubicin; Glucosamine; Humans; Isoxazoles; Lectins; Leukemia, Myeloid, Acute; N-Acetylneuraminic Acid; Pyrimidines; Sialic Acids

1985
Altered 5-azacytidine metabolism following 3-deazauridine treatment of L5178Y and human myeloblasts.
    Cancer research, 1980, Volume: 40, Issue:11

    The effect of 3-deazauridine pretreatment on 5-azacytidine metabolism was studied in suspension cultures of L5178Y murine leukemia. A 3-hr exposure to 2 microM 3-deazauridine followed by a 1-hr exposure to 5 microM [14C]-5-azacytidine resulted in a 2-fold increase in total intracellular 5-azacytidine accumulation compared to untreated controls. Under the same conditions, incorporation of 5-azacytidine into the acid precipitable fraction of L5178Y cells was increased 3-fold. Incorporation of 5-azacytidine into RNA increased 85% following 3-deazauridine pretreatment, but 5-azacytidine incorporation into DNA did not change significantly. In cells pretreated with 3-deazauridine, there was an 80% reduction of intracellular cytidine triphosphate, the natural feedback inhibitor of uridine-cytidine kinase, the rate-limiting enzyme in the phosphorylation of 5-azacytidine. Intracellular levels of 5-azacytidine triphosphate, the presumed lethal metabolite of 5-azacytidine, increased from 28.8 pmol/10(6) cells in control cells to 56.4 pmol/10(6) cells following 3-deazauridine treatment. The sequence of 3-deazauridine followed by 5-azacytidine demonstrated synergistic cell killing when measured by an in vitro soft-agar cloning assay. Similar biochemical alterations were also seen in human leukemic myeloblasts. It appears that 3-deazauridine-induced alterations in 5-azacytidine metabolism may account for the enhanced cytotoxicity of this drug sequence.

    Topics: 3-Deazauridine; Animals; Azacitidine; Biological Transport; Clone Cells; DNA, Neoplasm; Humans; Leukemia L5178; Leukemia, Experimental; Leukemia, Myeloid, Acute; Mice; Neoplasm Proteins; Ribonucleotides; RNA, Neoplasm; Uridine

1980
Simultaneous determination of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 3-deazauridine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
    Journal of chromatography, 1980, Dec-12, Volume: 221, Issue:2

    Topics: 3-Deazauridine; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cells, Cultured; Chromatography, High Pressure Liquid; Cytarabine; Cytidine Triphosphate; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Uracil Nucleotides; Uridine; Uridine Triphosphate

1980
Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells.
    Cancer research, 1978, Volume: 38, Issue:6

    When incubated with 1-beta-D-arabinofuranosylcytosine (ara-C), RPMI 6410 cells formed a hitherto unrecognized ara-C metabolite, 1-beta-D-arabinofuranosylcytosine diphosphate choline. This compound was characterized by (a) chromatographic behavior, (b) chemical and enzymatic hydrolysis, (c) phosphorus content, and (d) incorporation of [5-3H]ara-C and [methyl-14C]choline. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline by RPMI 6410 cells was enhanced in the presence of 3-deazauridine (DU) and was preceded by that of 1-beta-D-arabinofuranosylcytosine triphosphate. The antiproliferative effects of ara-C and DU toward RPMI 6410 cells were potentiated when the agents were present together. The anabolism of ara-C during a 24-hr interval of culture was markedly enhanced by the presence of DU; cellular concentrations of 1-beta-D-arabinofuranosylcytosine triphosphate and 1-beta-D-arabinofuranosylcytosine diphosphate choline were 5- and 15-fold higher than those in the absence of DU. This enhancement appears to be the basis of the potentiation of cytotoxicity resulting from combination of the agents. Pretreatment of RPMI 6410 cells with DU resulted in enhanced rates of cellular uptake of ara-C. ara-C uptake under these circumstances was blocked by the inhibitor of nucleoside transport, nitrobenzylthioinosine.

    Topics: 3-Deazauridine; Animals; Cell Division; Cells, Cultured; Choline; Cytarabine; Cytidine Diphosphate Choline; Drug Synergism; Humans; Hydrolysis; Leukemia, Experimental; Leukemia, Myeloid, Acute

1978
Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in neoplastic and normal cells.
    Cancer research, 1978, Volume: 38, Issue:6

    1-beta-D-Arabinofuranosylcytosine diphosphate choline was formed from 1-beta-D-arabinofuranosylcytosine (ara-C) during incubation in vitro of peripheral myeloblasts from patients with acute myelogenous leukemia and cultured cells (nonleukemic human lymphocytes, mouse lymphoma L5178Y, and HeLa); as well, 1-beta-D-arabinofuranosylcytosine diphosphate choline was formed in vivo in mouse leukemia L1210 cells and mouse liver. 3-Deazauridine enhanced the anabolism of ara-C in nonleukemic lymphocytes in vitro and leukemia L1210 cells in vivo but did not influence ara-C anabolism in the other cell types. In acute myelogenous leukemia myeloblasts incubated in vitro with ara-C, concentrations of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate were maximal after 8 hr of incubation and formation of the latter preceded that of 1-beta-D-arabinofuranosylcytosine diphosphate choline.

    Topics: 3-Deazauridine; Animals; Choline; Cytarabine; Cytidine Diphosphate Choline; Drug Synergism; Female; HeLa Cells; Leukemia L1210; Leukemia, Experimental; Leukemia, Myeloid, Acute; Liver; Lymphocytes; Mice; Mice, Inbred Strains

1978